Designer oxazolidinones schemes

This new family of oxazolidinones was described and shown to effectively displace compounds that bind the ribosomal 50S A-site (linezolid site), including chloramphenicol and Puromycin [80]. The structures of several family members (16-20) are depicted in Scheme 3. The reader is referred to the primary citations for tables of antibacterial activity data (as is the case for all case studies). Compounds such as 17 and 19 were compounds predicted to have good oral bioavailability in the QSAR model [79]. Compounds such as 16 were predicted to have good Haemophilus influenzae activity in that QSAR activity model [79]. The computational and crystallographically inspired design of novel oxazolidinones eventually led to Rib-X Pharmaceuticals clinical candidate, Radezolid (20), currently in Phase II clinical trials [31]. 

A recently new designed Wang resin supported Evans chiral auxiliary (52) has been shown to perform Evans asymmetric alkylation on solid support (Scheme 12.19) [34, 35], Preparation of the auxiliary started with coupling of Fmoc-piperidine-4-carboxylic acid to Wang resin. Subsequent removal of the Fmoc protection was followed by coupling to N-protected (2J ,3S)-3-amino-2-hydroxy-4-phenylbutanoic acid. After deprotection, the amino-alcohol moiety was converted into the oxazolidinone auxiliary 52 using carbonyldiimidazole (CDI). 

The abihties of the tube-in-tube design was further expanded by Buba et al. (2013EJOC4509). For the synthesis of the oxazolidinone 36, formaldehyde was used in the gaseous state by heating paraformaldehyde to 80 °C. The tube-in-tube reactor needs to be kept at a temperature higher than 80 °C to prevent polymerization and subsequent precipitation of paraformaldehyde onto the membrane surface. Formaldehyde reacted with Fmoc-protected alanine 35 in the presence of a catalytic amount ofp-tolue-nesulfonic acid in acetonitrile to achieve N-Fmoc-L-4-methyl-oxazohdin-5-one 36 in excellent yield (91% Scheme 9) (2013EJOC4509). 

A number of chiral auxiliaries has been designed for enantioselective 1,4-addition to a, -unsaturated carbonyl compounds. Chiral oxazolidinones are among the most efficient, affording the Michael-adducts with up to 99% ee. Asymmetric conjugate addition of an arylmagnesium reagent to cinnamoyloxazolidinone 151 is the key step in the synthesis of (+)-tolterodine 152, an important muscarinic receptor agonist (Scheme 2-58). 

---